UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
350 Hills Street, Suite 106, Richland, Washington 99354
(Address of Principal Executive Offices) (Zip Code)
(509) 375-1202
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
Common Stock, $0.001 par value |
ISR |
NYSE American |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On August 19, 2021, Isoray Medical, Inc. (“Medical”), a wholly owned subsidiary of Isoray, Inc., entered into Addendum No. 2 (the “Addendum”) to its supply contract with Joint Stock Company «Isotope», a Russian company (“JSC Isotope”), originally dated March 18, 2021, for the purchase of Cesium-131. The Addendum adds MedikorPharma-Ural LLC, a company incorporated in accordance with the laws of Russia (“Medikor”), as a supplier to supply enriched barium carbonate for the manufacture of Cesium-131 to JSC Isotope on behalf of Medical.
The Addendum is filed as Exhibit 10.1 to this Current Report on Form 8-K, and the above description of the Addendum is qualified in its entirety by reference to such exhibit.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
10.1 |
Addendum No. 2 to Supply Contract, dated August 19, 2021, by and between Isoray Medical, Inc. and Joint Stock Company. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 25, 2021
Isoray, Inc., a Delaware corporation
By: /s/ Lori A. Woods
Lori A. Woods, CEO
Exhibit 10.1
Certain identified information has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
Addendum No. 2 dated 2021.08.16 to
Contract No. 840/08625142/31/22-21
Date of signature: 2021.03.18
THE SELLER
Isotope - Regional Alliance, Joint-Stock Company (Isotope JSC)
Pogodinskaya str., 22, Moscow, 119435, Russia.
Phone: +7(495) 981-96-16
THE BUYER
The Company Isoray Medical Inc.
350 Hills Street, Suite 106
Richland, WA 99354-5411 USA
THE BUYER and THE SELLERS have mutually agreed about the following:
The following company is determined by the Buyer as a Supplier of the Goods, produced by JSC "SSC RIAR": MedikorPharma-Ural LLC, 620109, Sverdlovskaya region, Yekaterinburg, Krulya Street, 2, apartment 192, Tel.: 8(343) 270-75-29, E-mail: dpbugaev@gmail.com. The Buyer is responsible to the Seller for MedikorPharma-Ural LLC fulfillment of its obligations. The cost of services, provided by MedikorPharma-Ural LLC, shall not exceed USD [**] [**].
The present addendum is the integral part of contract 840/08625142/31/22-21 and may be signed by E-mail.
All other terms and conditions are in accordance with Contract No. 840/08625142/31/22-21, Appendices 1 and 2, Addendum 1.
| THE SELLER | THE BUYER | ||
| /s/ Konstantin Ershov | /s/ Jonathan Hunt | ||
| Konstantin Ershov | Jonathan Hunt | ||
| 19 Aug 2021 | 19 Aug 2021 | ||
| Head of Sales Department, JSC Isotope | Isoray - CFO |